Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,735
  • Shares Outstanding, K 67,349
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,190 K
  • 60-Month Beta -0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0786 +27.23%
on 01/27/20
0.1800 -44.44%
on 01/24/20
+0.0050 (+5.26%)
since 01/17/20
3-Month
0.0650 +53.85%
on 12/18/19
0.1800 -44.44%
on 01/24/20
-0.0425 (-29.82%)
since 11/19/19
52-Week
0.0650 +53.85%
on 12/18/19
0.6000 -83.33%
on 04/25/19
-0.3660 (-78.54%)
since 02/19/19

Most Recent Stories

More News
GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills

TAMPA, Florida , Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager...

GTBP : 0.1000 (+5.26%)
GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

TAMPA, Florida , Oct. 3, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™...

GTBP : 0.1000 (+5.26%)
GT Biopharma Announces HIV Trike™ Data to be Published

LOS ANGELES , Sept. 26, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager...

GTBP : 0.1000 (+5.26%)
GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics

TAMPA, Florida , Sept. 24, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager...

GTBP : 0.1000 (+5.26%)
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial

TAMPA, Florida , Sept. 12, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager...

GTBP : 0.1000 (+5.26%)
GT Biopharma Hires Chief Medical Officer Jeffery Miller, M.D.

TAMPA, FL / ACCESSWIRE / August 20, 2019 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKEa"c)...

GTBP : 0.1000 (+5.26%)
GT Biopharma GTB-1550

TAMPA, Florida , June 13, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company developing GTB-1550, a novel multi-target bispecific drug conjugate therapy for...

APOP : 2.34 (+1.74%)
GTBP : 0.1000 (+5.26%)
GT Biopharma Company Update

TAMPA, Florida , June 10, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (OTCQB: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK...

GTBP : 0.1000 (+5.26%)
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota

TAMPA, Florida , April 24, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary...

GTBP : 0.1000 (+5.26%)
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial

TAMPA, Florida , April 8, 2019 /PRNewswire/ --GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary...

GTBP : 0.1000 (+5.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GTBP with:

Key Turning Points

2nd Resistance Point 0.1063
1st Resistance Point 0.1031
Last Price 0.1000
1st Support Level 0.0937
2nd Support Level 0.0875

See More

52-Week High 0.6000
Fibonacci 61.8% 0.3956
Fibonacci 50% 0.3325
Fibonacci 38.2% 0.2694
Last Price 0.1000
52-Week Low 0.0650

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar